Published in PLoS One on November 24, 2009
Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature (2011) 3.61
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med (2017) 2.08
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta (2012) 2.05
Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. PLoS One (2011) 1.74
Microbial ecology of the murine gut associated with the development of dextran sodium sulfate-induced colitis. Inflamm Bowel Dis (2010) 1.44
Quantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models. BMC Bioinformatics (2014) 1.00
Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis. PLoS One (2013) 0.98
Intestinal epithelial cells and their role in innate mucosal immunity. Cell Tissue Res (2010) 0.92
Transcriptomic landscape of lncRNAs in inflammatory bowel disease. Genome Med (2015) 0.91
Antimicrobial peptides in gastrointestinal inflammation. Int J Inflam (2010) 0.86
Intestinal epithelium in inflammatory bowel disease. Front Med (Lausanne) (2014) 0.84
Molecular patterns in human ulcerative colitis and correlation with response to infliximab. Inflamm Bowel Dis (2014) 0.82
The Gdac1 locus modifies spontaneous and Salmonella-induced colitis in mice deficient in either Gpx2 or Gpx1 gene. Free Radic Biol Med (2013) 0.80
EGL-9 controls C. elegans host defense specificity through prolyl hydroxylation-dependent and -independent HIF-1 pathways. PLoS Pathog (2012) 0.80
Immune activation in HIV/HCV-infected patients is associated with low-level expression of liver expressed antimicrobial peptide-2 (LEAP-2). J Clin Pathol (2013) 0.79
ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation. Elife (2016) 0.79
DEFB1 gene 5' untranslated region (UTR) polymorphisms in inflammatory bowel diseases. Clinics (Sao Paulo) (2012) 0.78
Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab. Immunology (2013) 0.77
Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease. Sci Rep (2016) 0.77
Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis. PLoS One (2014) 0.77
An inducible and secreted eukaryote-like serine/threonine kinase of Salmonella enterica serovar Typhi promotes intracellular survival and pathogenesis. Infect Immun (2014) 0.76
Characterization of candidate genes in inflammatory bowel disease-associated risk loci. JCI Insight (2016) 0.76
Microbiota regulate intestinal epithelial gene expression by suppressing the transcription factor Hepatocyte nuclear factor 4 alpha. Genome Res (2017) 0.76
Epigenetic regulation of lncRNA connects ubiquitin-proteasome system with infection-inflammation in preterm births and preterm premature rupture of membranes. BMC Pregnancy Childbirth (2015) 0.75
Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140. Sci Immunol (2017) 0.75
Quantifying the relative immune cell activation from whole tissue/organ-derived differentially expressed gene data. Sci Rep (2017) 0.75
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 22.57
Unravelling the pathogenesis of inflammatory bowel disease. Nature (2007) 18.52
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell (1993) 11.95
Experimental models of inflammatory bowel disease. Gastroenterology (1995) 6.28
Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell (1993) 5.99
Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology (2004) 5.19
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology (1998) 5.02
Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet (1991) 5.02
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut (2004) 4.39
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 4.08
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut (2000) 3.69
Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut (2008) 2.90
T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol (1997) 2.76
Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol (2003) 2.62
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2003) 2.06
Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol (2008) 1.85
Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut (2008) 1.53
Antimicrobial peptides: natural effectors of the innate immune system. Semin Immunopathol (2007) 1.43
beta-Defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin Exp Immunol (2004) 1.35
Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol (2007) 1.25
Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol (2006) 1.21
Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol (2007) 1.14
Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut (2007) 1.11
Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease. PLoS One (2009) 1.01
Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver. Protein Sci (2003) 0.88
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Natalizumab for active Crohn's disease. N Engl J Med (2003) 6.44
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet (2008) 5.49
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science (2008) 4.38
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis (2012) 3.89
Chromosome instability is common in human cleavage-stage embryos. Nat Med (2009) 3.85
In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J Cell Sci (2006) 3.82
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis (2012) 3.69
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology (2004) 3.40
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology (2008) 3.36
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut (2011) 3.36
The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am J Gastroenterol (2004) 3.25
Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet (2005) 3.24
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet (2010) 3.22
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype. Blood (2013) 3.07
Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol (2004) 2.99
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol (2002) 2.94
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol (2009) 2.92
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis (2007) 2.89
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet (2008) 2.67
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut (2011) 2.58
The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis (2012) 2.55
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut (2007) 2.53
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology (2003) 2.37
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis (2009) 2.33
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology (2009) 2.26
Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol (2010) 2.19
Biological therapies for inflammatory bowel diseases. Gastroenterology (2009) 2.18
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology (2002) 2.15
An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet (2007) 2.14
Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol (2007) 2.14
Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med (2009) 2.10
Using ribosomal protein genes as reference: a tale of caution. PLoS One (2008) 2.06